

ART 34 AMDT

Claims:

1. A method of assessing an individual for a cancer condition comprising;

providing a tissue sample obtained from said individual,
determining the presence in said sample of one or more cells comprising a plexinB1 nucleic acid sequence having one or more mutations in a coding region of said plexinB1 nucleic acid sequence,

the presence of said one or more cells being indicative of said individual having a cancer condition.

2. A method according to claim 1 wherein said one or more mutations alter the activity of a plexin polypeptide encoded by said nucleic acid.

3. A method according to claim 1 or claim 2 wherein the plexin B1 polypeptide comprises one or more mutations in the cytoplasmic domain thereof.

4. A method according to any preceding claim wherein the one or more mutations are at one or more mutation sites selected from the group consisting of T1697, T1733, T1776, T1795, T1802, P1597, P1798, F1711, G1602, L1815, N1735, R1904, A1730, G1728, and K1613.

BEST AVAILABLE COPY

ART 34 AMDT

5. A method according to claim 4 wherein the one or more mutations are selected from the group consisting of T1697A, T1733I, T1776A, T1795A, T1802A, P1597L, P1597S, P1798S, F1711I, G1602T, L1815P, N1735S, R1904W, A1730T, G1728S, L1815F, and K1613E.
6. A method according to claim 5 wherein the polypeptide comprises a mutation selected from the group consisting of T1795A, P1597S, P1597L, and L1815P.
7. A method according to claim 5 wherein the polypeptide comprises the mutation T1795A.
8. A method according to any one of the preceding claims wherein the cancer condition is prostate cancer or breast cancer.
9. A method according to any preceding claim wherein the presence of said one or more cells is determined by detecting the presence of said plexinB1 polypeptide.
10. A method of determining the invasiveness of a cancer cell in a sample obtained from an individual, the method comprising, determining the presence or absence in said cell of a plexin B1 polypeptide having one or more mutations therein, the presence of said plexin B1 polypeptide being indicative that the cell is invasive.

ART 34 AMDT

62

11. A method according to claim 10 wherein said one or more mutations alter the activity of a plexin polypeptide encoded by said nucleic acid.

12. A method according to claim 10 or 11 wherein the plexinB1 polypeptide comprises one or more mutations in the cytoplasmic domain thereof.

13. A method according to claim 12 wherein the one or more mutations are at one or more mutation sites selected from the group consisting of T1697, T1733, T1776, T1795, T1802, P1597, P1798, F1711, G1602, L1815, N1735, R1904, A1730, G1728, and K1613.

14. A method according to claim 13 wherein the one or more mutations are selected from the group consisting of T1697A, T1733I, T1776A, T1795A, T1802A, P1597L, P1597S, P1798S, F1711I, G1602T, L1815P, N1735S, R1904W, A1730T, G1728S, L1815F, and K1613E.

15. A method according to claim 14 wherein the polypeptide comprises a mutation selected from the group consisting of T1795A, P1597L, P1597S, and L1815P.

16. A method according to claim 13 wherein the polypeptide comprises the mutation T1795A.

ART 34 AMDT

17. A method according to any one of the preceding claims
 wherein the cancer condition is prostate cancer or breast
 cancer.

18. A method according to any one of claims 10 to 17 wherein
 the presence of said one or more cells is determined by
 detecting the presence of said plexinB1 polypeptide.

19. A method of identifying and/or obtaining a putative anti-
 cancer agent, the method comprising;

contacting a plexinB1 polypeptide with a test compound,
 wherein the plexinB1 polypeptide comprises one or more
 mutations, and;

determining the activity of the plexinB1 polypeptide in
 the presence relative to the absence of test compound.

20. A method according to claim 19 wherein the one or more
 mutations are in the cytoplasmic domain of the plexinB1
 polypeptide.

21. A method according to claim 20 wherein the one or more
 mutations are at one or more mutation sites selected from the
 group consisting of T1697, T1733, T1776, T1795, T1802, P1597,
 P1798, F1711, G1602, L1815, N1735, R1904, A1730, G1728, and
 K1613.

22. A method according to claim 21 wherein the one or more mutations are selected from the group consisting of T1697A, T1733I, T1776A, T1795A, T1802A, P1597L, P1597S, P1798S, F1711I, G1602T, L1815P, N1735S, R1904W, A1730T, G1728S, L1815F, and K1613E.

23. A method according to any one of claims 19 to 22 wherein the plexinB1 polypeptide is expressed on the surface of a cell

24. A method according to claim 23 wherein the activity is plexinB1-mediated anchorage independent growth of said cell.

25. A method according to any one of claims 19 to 23 wherein the activity of the plexinB1 polypeptide is determined by determining the binding of said polypeptide to one or more of semaphorin4D, active Rac1, neuropilin, PDZ-RhoGEF and LARG and other components of the semaphorin signalling pathway interacting with plexinB1.

26. A method according to any one of claims 19 to 23 wherein the activity of the plexinB1 polypeptide is determined by determining the activation of Rho GTPase.

27. A method according to any one of claims 19 to 23 comprising the further step of:

contacting a wild-type plexinB1 polypeptide with the test compound, and;

determining the activity of the wild-type plexinB1 polypeptide.

28. A method according to any one of claims 19 to 23 comprising the further steps of;

contacting the mutant plexinB1 polypeptide with the test compound in the presence of a wild-type plexinB1, and;

determining the activity of the wild-type plexinB1 polypeptide.

29. A method of identifying and/or obtaining a compound as a putative anti-cancer agent, the method comprising; contacting a plexinB1 nucleic acid with a test compound, wherein the plexinB1 nucleic acid comprises one or more mutations in a coding region of the nucleic acid, and; determining the expression of the plexinB1 nucleic acid in the presence relative to the absence of test compound.

30. A method according to claim 29 wherein the one or more mutations are in a region of the nucleic acid which encodes the cytoplasmic domain of the plexinB1 polypeptide.

31. A method according to claim 30 wherein the one or more mutations are at one or more mutation sites selected from the group consisting of 5059, 5060, 5074, 5107, 5359, 5401, 5452, 5458, 5468, 5474, 5596, 5653, 5662, 5674, 5713, 5714, and 5980 of the plexinB1 coding sequence.

ART 34 ANDT

32. A method according to claim 30 wherein the one or more mutations are selected from the group consisting of C5059T, C5060T, G5074A, A5107G, A5359G, T5401A, G5452A, G5458A, T5468C, A5474G, A5596G, A5653G, C5662T, A5674G, C5713T, T5714C and C5980T.

33. A method according to claim 29 further comprising determining the increase in the expression of wild-type plexin B1 in the presence of said test compound.

34. A method according to any one of claims 36 to 41 comprising determining a decrease in the expression of mutant plexin B1 in the presence of said test compound

35. A method according to any one of claims 19 to 34 comprising identifying the test compound as a putative anti-cancer agent.

36. A method according to claim 35 comprising isolating and/or purifying the test compound.

37. A method according to claim 36 comprising modifying the test compound to optimise its pharmaceutical properties.

38. A method according to any one of claims 35 to 37 comprising formulating said test compound with a pharmaceutically acceptable excipient.

39. A method of producing a pharmaceutical compound comprising the steps of;
identifying a compound using any one of claims 19-37 and;
formulating said test compound with a pharmaceutically acceptable excipient.

40. A compound identified as a putative anti-cancer agent by a method of claim 35.

41. A pharmaceutical composition comprising the compound of claim 40 and a pharmaceutically acceptable excipient.

42. A compound according to claim 40 for use in a method of treatment

43. Use of a compound according to claim 40 in the manufacture of a medicament for use in the treatment of cancer.

44. A nucleic acid encoding mutant plexinB1 polypeptide or its complement or a fragment thereof for use in a method of treatment.

ART 34 AMDT

68

45. A nucleic acid according to claim 44 wherein the mutant plexinB1 polypeptide has one or more mutations in the cytoplasmic domain.

46. A nucleic acid according to claim 45 wherein the one or more mutations are at one or more mutation sites selected from the group consisting of T1697, T1733, T1776, T1795, T1802, P1597, P1798, F1711, G1602, L1815, N1735, R1904, A1730, G1728, and K1613.

47. A nucleic acid according to claim 46 wherein the one or more mutations are selected from the group consisting of T1697A, T1733I, T1776A, T1795A, T1802A, P1597L, P1597S, P1798S, F1711I, G1602T, L1815P, N1735S, R1904W, A1730T, G1728S, L1815F, and K1613E

48. A nucleic acid according to any one of claims 43 to 47 for use in a method of treating cancer.

49. Use of nucleic acid encoding plexinB1 or its complement or a fragment thereof in the manufacture of a medicament for the treatment of cancer.

50. Use of nucleic acid encoding a mutant plexinB1 polypeptide or its complement or a fragment thereof in the manufacture of a medicament for the treatment of cancer.

ART 34 AMDT

51. Use according to claim 50 wherein the mutant plexinB1 polypeptide has one or more mutations in the cytoplasmic domain.

52. Use according to claim 50 wherein the one or more mutations are at one or more mutation sites selected from the group consisting of T1697, T1733, T1776, T1795, T1802, P1597, P1798, F1711, G1602, L1815, N1735, R1904, A1730, G1728, and K1613.

53. Use according to claim 52 wherein the one or more mutations are selected from the group consisting of T1697A, T1733I, T1776A, T1795A, T1802A, P1597L, P1597S, P1798S, F1711I, G1602T, L1815P, N1735S, R1904W, A1730T, G1728S, L1815F and K1613E.

54. A method of treating a cancer condition in an individual, the method comprising introducing nucleic acid according to claims 49-53 in to one or more cells of said individual.

55. A method of screening for an antibody molecule specific for a mutant plexinB1, the method comprising;
providing a population of antibody molecules specific for mutant plexinB1,
contacting said population with a normal plexinB1 polypeptide,
identifying one or more members of said population which bind preferentially to mutant plexinB1 relative to normal plexinB1.

34 ANDT

56. An antibody molecule which specifically binds to a mutant plexinB1 polypeptide.

57. A method of treating a cancer condition in an individual, the method comprising reducing the activity of mutant plexinB1 polypeptide in one or more cells of said individual.

58. A method according to claim 57 wherein the activity of mutant plexinB1 polypeptide is reduced by administering an antagonist of mutant plexinB1 to said individual.

59. A method according to claim 57 wherein the activity of mutant plexinB1 polypeptide is reduced by decreasing or abolishing expression of the mutant plexin B1 polypeptide.

60. A method according to claim 57 wherein expression of the mutant plexin B1 polypeptide is abolished or reduced by administering a nucleic acid according to any one of claims 43 to 47.

61. A method of reducing the invasiveness of a tumour in an individual comprising reducing the activity of mutant plexinB1 polypeptide in one or more cells of said tumour.

62. A method according to claim 61 wherein the activity of mutant plexinB1 polypeptide is reduced by administering an antagonist of mutant plexinB1 to said individual.

PAGE 34 AMEND

63. A method according to claim 61 wherein the activity of mutant plexinB1 polypeptide is reduced by decreasing or abolishing expression of a mutant plexinB1 polypeptide.

64. A method according to claim 61 wherein expression of a mutant plexin B1 polypeptide is abolished or reduced by administering a nucleic acid according to any one of claims 43 to 47.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.